CureVac NV

CureVac N.V. is a biopharmaceutical company founded in 2002 and headquartered in Tübingen, Germany. The firm is engaged in the development of therapies and vaccines based on messenger RNA (mRNA). Serving a worldwide audience, the company's primary focus is on developing vaccines for infectious diseases and drugs for the treatment of various cancers and rare diseases. CureVac was the first company in the world to successfully harness mRNA and use it for medical purposes. The firm launched as a public company in August 2020 and is listed on the NASDAQ GM, trading under the ticker CVAC. In December 2020, the CVAC share price showed a 52-week low of $36.15 and a 52-week high of $106.68, with a market cap of $18.89bn. The CVAC stock value increased by almost 3.5x on the company’s first day of trading as a public company, possibly due to the high profile of some of the vaccines it has in the pipeline, including a COVID-19 vaccine in phase II of clinical trials, as well as several other important vaccines at either phase I or the pre-clinical stage. CureVac N.V. is involved in every step of mRNA therapeutics development, from discovery to production. The company holds around 700 granted patents. Add CVAC stock to your eToro portfolio today and start tracking price movements and news updates.